Suppr超能文献

免疫功能正常患者在阿托伐醌治疗下弓形虫性视网膜脉络膜炎复发

Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient.

作者信息

Baatz Holger, Mirshahi Alireza, Puchta Joachim, Gümbel Hermann, Hattenbach Lars-Olof

机构信息

Recklinghausen Eye Center, Recklinghausen, Germany.

出版信息

Ocul Immunol Inflamm. 2006 Jun;14(3):185-7. doi: 10.1080/09273940600659740.

Abstract

PURPOSE

To report a case of toxoplasma retinochoroiditis reactivation in an immunocompetent patient under atovaquone therapy.

METHODS

Case report.

RESULTS

A healthy woman with a history of bilateral toxoplasma retinochoroiditis since childhood presented with a reactivation of toxoplasma retinochoroiditis. Because earlier treatment regimens had either produced intolerable side effects and/or were deemed ineffective for the prevention of reactivation, the patient was started on atovaquone suspension (750 mg three times a day). After initial regression of the lesion and still under atovaquone therapy, the patient presented again five weeks later with worsened best-corrected visual acuity. Examination showed that the lesion had expanded again and more cells were present in the vitreous.

CONCLUSIONS

To our knowledge, this is the first report of a reactivation of toxoplasma retinochoroiditis in an immunocompetent patient under atovaquone therapy, possibly indicating tachyzoite resistance to atovaquone.

摘要

目的

报告1例免疫功能正常的患者在接受阿托伐醌治疗时弓形虫视网膜脉络膜炎复发的病例。

方法

病例报告。

结果

一名自幼患有双侧弓形虫视网膜脉络膜炎的健康女性出现弓形虫视网膜脉络膜炎复发。由于早期治疗方案要么产生了无法耐受的副作用,和/或被认为对预防复发无效,该患者开始服用阿托伐醌混悬液(每日3次,每次750mg)。病变最初消退后,且仍在接受阿托伐醌治疗时,患者在5周后再次就诊,最佳矫正视力恶化。检查显示病变再次扩大,玻璃体内出现更多细胞。

结论

据我们所知,这是首次报告免疫功能正常的患者在接受阿托伐醌治疗时弓形虫视网膜脉络膜炎复发,这可能表明速殖子对阿托伐醌耐药。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验